Condition: Atrial Fibrillation · Obesity · Sponsor: The Cleveland Clinic
This is a single center randomized double blind controlled study of patients (BMI ≥ 27 kg/m2) with obesity and Atrial Fibrillation (AFIB) randomized to Tirzepatide vs. placebo. It is expected that the significant weight loss with Tirzepatide will result in improved control, management, symptom severity, and burden of AFIB at 12 months.
This description comes directly from the study's public registry record.
Jeannine M Ramsey, RN, BSN · 216-559-7942 · ramseyj8@ccf.org
Yuki Kuramochi, RN, BSN · 216-445-4063 · kuramoy@ccf.org
Always discuss trial participation with your own doctor first.
| Cleveland Clinic | Cleveland, Ohio, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06802081